$8.88 is low, but still with PE of 19, for a compnay has 17% growth rate,I wouldn't it's say super cheap, but reasonable, only if they can deliver what they forecasted.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%